Nectar Lifesciences Limited has informed the Exchange about Update on Acquisition
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences Limited has completed the acquisition of the entire paid-up equity share capital of Avensis Exports Private Limited (AEPL) on March 06, 2026. The total cash consideration paid was INR 24,96,000 (about ₹24.96 lakhs), settled through normal banking channels. Following this transaction, AEPL has become a Wholly Owned Subsidiary of Nectar Lifesciences. This announcement is an update to the company's earlier disclosure dated March 02, 2026, filed under SEBI LODR Regulations.
The deal size is very small (under ₹25 lakhs), so the financial impact on Nectar Lifesciences is negligible. AEPL becoming a wholly owned subsidiary may support the company's business expansion plans, but shareholders should monitor further disclosures about AEPL's operations and strategic role.